Wall St futures flat amid US-China trade jitters; bank earnings in focus
NEW YORK - Anavex Life Sciences Corp. (NASDAQ:AVXL), a biotech company with a market capitalization of $818 million that has delivered an impressive 86% return over the past year, announced Friday that Prof. Dr. Timo Grimmer delivered a presentation on oral blarcamesine for Alzheimer’s disease at the 35th Alzheimer Europe Conference. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt on its balance sheet.
Dr. Grimmer, a member of Anavex’s Scientific Advisory Board and National Coordinating Investigator for the company’s Phase IIb/III blarcamesine study, presented on the potential convenience benefits of the oral treatment for patients and families.
Blarcamesine, also known as ANAVEX 2-73, is an orally available drug candidate designed to target SIGMAR1 and muscarinic receptors. The compound has completed a Phase 2a and Phase 2b/3 clinical trial for Alzheimer’s disease, along with studies in Parkinson’s disease dementia and Rett syndrome.
The company’s pipeline also includes ANAVEX 3-71, which targets similar receptors and has shown effects against cognitive deficits, amyloid, and tau pathologies in preclinical Alzheimer’s disease models.
Anavex Life Sciences focuses on developing treatments for various neurological conditions including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and rare diseases such as Rett syndrome.
The presentation information was shared in a company press release. The investigational treatment discussed has not received health authority approval, and there is no guarantee it will successfully complete clinical development.
In other recent news, Anavex Life Sciences has reported significant advancements in its clinical studies. The company announced positive results from its Phase 2 study of ANAVEX3-71 for schizophrenia, achieving the primary endpoint of safety and tolerability in adults on stable antipsychotic medication. No serious or severe treatment-emergent adverse events were reported, consistent with prior studies. Additionally, Anavex has successfully developed a once-daily oral tablet formulation for ANAVEX3-71, demonstrating superior pharmacokinetics compared to the current immediate-release capsule.
H.C. Wainwright has maintained its Buy rating on Anavex Life Sciences, with a price target of $42.00, following these positive developments. The firm also reiterated its rating after new data from a Phase 2b/3 trial of blarcamesine in Alzheimer’s disease showed minimal decline in patients over 48 weeks. These recent developments highlight the ongoing progress in Anavex’s clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.